Catalyzing
immunotherapy

CatalYm is a pioneer in translating the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors.

Catalym Corporate Video

How we neutralize GDF-15 within the tumor microenvironment

Click to see the movie.

What
drives us

Phil L’Huillier

Chief Executive Officer

As a pioneer in unraveling the role of GDF-15 in immunosuppression, we are determined to leverage our knowledge and bring the power of GDF-15 to treat as many cancer patients as possible.
Christine Schuberth-Wagner

Chief Scientific Officer

When we identified GDF-15, we immediately recognized its potential for reversing cancer-mediated immunosuppression. It is exciting to further explore its cellular mechanisms and receive external confirmation and validation of GDF-15 as a key player in the immuno-oncology space.
Eugen Leo

Chief Medical Officer

Currently, the vast majority of cancer patients still does not benefit from immunotherapy. Data suggest that GDF-15 plays a significant role in making many tumors inaccessible to existing immunotherapies. That is why we believe, blocking it represent a major step forward in enhancing response depth and duration for many cancer indications.
Anne Burger

Chief Financial Officer

The entrepreneurial mindset and experience of our team in combination with the strong support and financial backing of our shareholders, enable us to explore the potential of GDF-15 for currently non-responding cancer patients in a smart and efficient way. Paving the way to serve innovative combination therapies for cancer patients with high unmet medical need.